
    
      Patients who complete all 24 weeks of the double-blind study E2020-E044-316 (NCT00165815)
      will be eligible for the open label extension study. Patients and caregiver/study partner
      will need to provide additional written informed consent to participate in the open label
      extension study. Safety and tolerability will be assessed after 4, 8 12, 24, 36 and 52 weeks.
      Cognition, Global Clinical Function, Activities of Daily Living, and Behaviour will be
      assessed after 24, and 52 weeks.
    
  